Incyte (INCY) Q2 Revenue Tops Views

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Incyte (INCY) Q2 Revenue Tops Views

Incyte Reports 2018 Second Quarter Financial Results and Updates on Key Clinical Programs

July 31, 2018 7:00 AM EDT

Total product-related revenues of $421 million in Q2 2018, representing 29 percent growth over the same period last year; Jakafi® (ruxolitinib) revenues of $346 million in Q2 2018, representing 25 percent growth over the same period last year Pivotal REACH1 study of Jakafi in steroid-refractory acute GVHD met primary endpoint; sNDA submission expected in Q3 2018 Later-stage portfolio provides potential for accelerated growth from multiple near-to-market opportunities

Second Quarter Conference Call and Webcast Scheduled Today at 8:00 a.m. EDT

WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte... More